ReviewBioMed research international2013
Virosome presents multimodel cancer therapy without viral replication.
Review in BioMed research international, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 30 citations in OpenAlex.
- Advances in the Functionalization of Vaccine Delivery Systems: Innovative Strategies and Translational Perspectives.Pharmaceutics · 2025Review
- Therapeutic applications of nanobiotechnology.Journal of nanobiotechnology · 2023Review
- Virosome-based nanovaccines; a promising bioinspiration and biomimetic approach for preventing viral diseases: A review.International journal of biological macromolecules · 2021Review
- CXCL2 combined with HVJ-E suppresses tumor growth and lung metastasis in breast cancer and enhances anti-PD-1 antibody therapy.Molecular therapy oncolytics · 2021Article
- Nano-Biomimetic Drug Delivery Vehicles: Potential Approaches for COVID-19 Treatment.Molecules (Basel, Switzerland) · 2020Review
- Bioinspired and Biomimetic Nanotherapies for the Treatment of Infectious Diseases.Frontiers in pharmacology · 2019Review
- Nanoparticles: augmenting tumor antigen presentation for vaccine and immunotherapy treatments of cancer.Nanomedicine (London, England) · 2017Review
- Salmonella mediated the hemagglutinating virus of Japan-envelope transfer suppresses tumor growth.Oncotarget · 2017Article
- Pulmonary Delivery of Virosome-Bound Antigen Enhances Antigen-Specific CD4Frontiers in immunology · 2017Article
- An RNA Molecule Derived From Sendai Virus DI Particles Induces Antitumor Immunity and Cancer Cell-selective Apoptosis.Molecular therapy : the journal of the American Society of Gene Therapy · 2016Article
- Salmonella as an innovative therapeutic antitumor agent.International journal of molecular sciences · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A virosome is an artificial envelope that includes viral surface proteins and lacks the ability to produce progeny virus. Virosomes are able to introduce an encapsulated macromolecule into the cytoplasm of cells using their viral envelope fusion ability. Moreover, virus-derived factors have an adjuvant effect for immune stimulation. Therefore, many virosomes have been utilized as drug delivery vectors and adjuvants for cancer therapy. This paper introduces the application of virosomes for cancer treatment. In Particular, we focus on virosomes derived from the influenza and Sendai viruses which have been widely used for cancer therapy. Influenza virosomes have been mainly applied as drug delivery vectors and adjuvants. By contrast, the Sendai virosomes have been mainly applied as anticancer immune activators and apoptosis inducers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.